Literature DB >> 10715260

Clinical outcomes after ablation and pacing therapy for atrial fibrillation : a meta-analysis.

M A Wood1, C Brown-Mahoney, G N Kay, K A Ellenbogen.   

Abstract

BACKGROUND: Radiofrequency ablation of the atrioventricular node and permanent pacing are used for symptomatic relief in patients with medically refractory atrial fibrillation. In this study, meta-analysis was used to clarify clinical outcomes and survival after ablation and pacing therapy using data from the published literature. METHODS AND
RESULTS: We used 21 studies with a total of 1181 patients in the meta-analysis. All patients had medically refractory atrial tachyarrhythmias, primarily atrial fibrillation (97%). Nineteen measures of clinical outcome, encompassing quality of life, ventricular function, exercise duration, and healthcare use, were derived from the studies. The meta-analysis demonstrated significant improvement after ablation and pacing therapy in all outcome measures except fractional shortening, which demonstrated a trend toward improvement (P=0.08). Ejection fraction did show significant improvement (P<0.001). The calculated 1-year total and sudden death mortality rates after ablation and pacing therapy were 6.3% and 2.0%, respectively.
CONCLUSIONS: Ablation and pacing therapy improves a broad range of clinical outcomes for patients with medically refractory atrial fibrillation. The calculated 1-year mortality rates after this therapy are low and comparable with medical therapy.

Entities:  

Mesh:

Year:  2000        PMID: 10715260     DOI: 10.1161/01.cir.101.10.1138

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  62 in total

Review 1.  Science, medicine, and the future: Radiofrequency ablation for atrial fibrillation.

Authors:  N R Grubb; S Furniss
Journal:  BMJ       Date:  2001-03-31

Review 2.  Trials of pacing to control ventricular rate during atrial fibrillation.

Authors:  Mark A Wood
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

Review 3.  Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins.

Authors:  F De Rienzo; R R Gabdoulline; R C Wade; M Sola; M C Menziani
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

4.  Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?

Authors:  Stanley Nattel
Journal:  CMAJ       Date:  2004-09-28       Impact factor: 8.262

Review 5.  Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities.

Authors:  Michiel Rienstra; Steven A Lubitz; Saagar Mahida; Jared W Magnani; João D Fontes; Moritz F Sinner; Isabelle C Van Gelder; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2012-06-12       Impact factor: 29.690

Review 6.  Management of atrial fibrillation.

Authors:  Gregory Y H Lip; Antonio Tello-Montoliu
Journal:  Heart       Date:  2006-08       Impact factor: 5.994

Review 7.  Rate control in the medical management of atrial fibrillation.

Authors:  A J Camm; I Savelieva; G Y H Lip
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

8.  Nonpharmacological Treatment of Atrial Fibrillation: What Is the Role of Device Therapy?

Authors:  Lucie Riedlbauchová; Václav Durdil; Jakub Honěk; Josef Veselka
Journal:  Int J Angiol       Date:  2020-04-28

9.  Atrioventricular Nodal Catheter Ablation in Atrial Fibrillation Complicating Congestive Heart Failure.

Authors:  Osmar Antonio Centurión; Karina Elizabeth Scavenius; Laura B García; Luis Miño; Judith Torales; Orlando Sequeira
Journal:  J Atr Fibrillation       Date:  2018-06-30

10.  Pulmonary vein antrum isolation, atrioventricular junction ablation, and antiarrhythmic drugs combined with direct current cardioversion: survival rates at 7 years follow-up.

Authors:  Kai Sonne; Dimpi Patel; Prasant Mohanty; Luciana Armaganijan; Lucie Riedlbauchova; Moataz El-Ali; Luigi Di Biase; Preeti Venkatraman; Mazen Shaheen; Marketa Kozeluhova; Robert Schweikert; J David Burkhardt; Robert Canby; Oussama Wazni; Walid Saliba; Andrea Natale
Journal:  J Interv Card Electrophysiol       Date:  2009-11       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.